BioSpace3d
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
Medscape2d
Drug Labels Often Neglect to Inform About Obesity Dosing
Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...
pharmaphorum2h
Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...
FDA pick may differ from HHS head RFK Jr. on some key areas
Martin Makary, an author and surgeon at Johns Hopkins University, has appeared frequently on Fox News to talk about health ...
STAT2d
1 in 6 young people will have obesity by 2050, analysis predicts
Republicans trying to find billions of Medicaid dollars to pay for tax cuts now say that any reduction in Medicaid spending ...
Opinion
Opinion: Connecticut’s balanced approach to obesity drug coverage and health care reform
The Department of Social Services remains committed to exploring policy solutions that maximize health outcomes while maintaining fiscal sustainability ...
STAT13d
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
EurekAlert!8d
The Obesity Society commends FDA's resolution of obesity drug shortages, calls for enforcement against unauthorized compounding
ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...
The Washington Post13d
FDA says Ozempic shortage is over, chilling boom in off-brand versions
As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the ...
BioSpace1d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...